Phio Pharmaceuticals Corp. - PHIO Earnings per share for the trailing year

Phio Pharmaceuticals is insulated from market cycles and macroeconomic shocks due to the specific nature of its cancer drug development. The YoY EPS volatility over the last 12 months confirms this stability, where the 42.80 parameter determines the metric's magnitude. The company's foundation is the innovative INTASYL system for immune cell modification, while the seamless operation of its molecular laboratories ensures the continuity of its scientific research.
Phio Pharmaceuticals - analytical breakdowns and key metrics (PHIO)

For the biotechnology company Phio Pharmaceuticals (PHIO), which is developing RNA interference in immuno-oncology, this indicator captures the annual trend of net earnings per share over a rolling period. By analyzing the historical EPS YoY TTM delta, an investor assesses the monetization efficiency of patent barriers and clinical protocols, where any sharp decline in the metric signals a decrease in the business's fundamental stability.